EDIT vs VTR · rev $32.3M vs P/E 149, rev $4.92B
Editas Medicine Inc (EDIT) versus Ventas Inc (VTR) — a side-by-side from cached financials, not a winner call.
Editas Medicine Inc (EDIT) is a biotechnology company listed on NASDAQ.
Ventas Inc (VTR) is a reit - healthcare facilities company listed on NYSE.
Latest reported EDIT revenue for 2024-12-31 was $32.3M. Net income was -$237.1M. Revenue was down 58.6% from 2023-12-31 to 2024-12-31. EDIT currently screens at market cap $375.2M.
Latest reported VTR revenue for 2024-12-31 was $4.92B. Net income was $88.4M. Revenue was up 9.5% from 2023-12-31 to 2024-12-31. VTR currently screens at market cap $39.94B and trailing P/E 149.4.
EDIT currently screens at market cap $375.2M. VTR currently screens at market cap $39.94B and trailing P/E 149.4.
Not investment advice. Open the EDIT and VTR stock pages for the full models.
Not investment advice.